PRDM players in central nervous system cancers: State of the art and future perspectives

Read full text Summarise with VIRAT
Authors: Erika Di Zazzo, Marzia Di Donato, Monica Rienzo, Amelia Casamassimi, Donatella Fiore, Maria Chiara Proto, Patrizia Gazzerro, Ciro Abbondanza
Cited by: 0
References: 99

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Despite major advances in understanding the molecular landscape of brain cancer, diagnosis is challenging and current treatment options remain largely ineffective. This underscores the urgent need to identify further genes and molecular pathways that could serve as therapeutic targets. PR (PRDI-BF1 and RIZ) domain-containing (PRDM) proteins, long recognized as key regulators in several cancer types, represent an emerging, yet still poorly understood, determinant of brain cancers. In this manuscript, we review current knowledge on the involvement of PRDM proteins (PRDMs) in central nervous system malignancies, suggesting their potential as diagnostic and prognostic biomarkers. We further discuss therapeutic perspectives, including strategies aimed at modulating PRDMs expression, targeting PRDMs-driven pathways, or affecting their enzymatic activities. Together, these insights position PRDMs as promising candidates for next-generation mechanism-based interventions that could optimize brain cancer treatment.

Fields of Study & Subjects

Glioma Diagnosis and Treatment Chromatin Remodeling and Cancer Cancer-related gene regulation

Publication details

Journal / source
Critical Reviews in Oncology/Hematology
Volume
222
Pages
105293–105293
Publication date
21 March 2026
Language
EN